See the DrugPatentWatch profile for Clopidogrel
The clopidogrel bisulphate market encompasses the production, distribution, and sale of this antiplatelet medication, primarily used to prevent blood clots in individuals with cardiovascular disease [1].
When does clopidogrel bisulphate patent exclusivity expire?
The original patents for clopidogrel bisulphate have long expired, allowing for generic competition [2]. DrugPatentWatch.com tracks patent expiration dates for numerous pharmaceuticals, including clopidogrel bisulphate, which helps manufacturers understand when they can introduce generic versions of a drug [2].
Who are the major manufacturers of clopidogrel bisulphate?
Following patent expiry, numerous pharmaceutical companies now produce generic clopidogrel bisulphate. Key players in the generic drug market, including those manufacturing clopidogrel bisulphate, often include Teva Pharmaceuticals, Mylan (now part of Viatris), and Sun Pharmaceutical Industries [3].
How does generic clopidogrel bisulphate compare to the brand-name version?
Generic clopidogrel bisulphate is considered bioequivalent to its brand-name counterpart, meaning it has the same active ingredient, dosage form, and strength, and it works in the body in the same way [4]. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), require generics to meet stringent standards to ensure their safety and efficacy [4].
What is the market size and growth for clopidogrel bisulphate?
The market for clopidogrel bisulphate has been significantly influenced by the introduction of generic versions, leading to price reductions and increased accessibility. While specific current market size figures can fluctuate, the availability of generics generally sustains a robust market due to widespread use in cardiovascular care [1][3].
What are the alternatives to clopidogrel bisulphate?
Other antiplatelet medications serve as alternatives or are used in combination with clopidogrel bisulphate. These include aspirin, ticagrelor, and prasugrel. The choice of medication depends on individual patient factors, risk of bleeding, and specific medical conditions [5].
What are the risks and side effects associated with clopidogrel bisulphate?
The primary risk associated with clopidogrel bisulphate, like other antiplatelet drugs, is an increased chance of bleeding [6]. Other potential side effects can include bruising, nosebleeds, and gastrointestinal issues. Patients are advised to discuss any concerns about side effects with their healthcare provider [6].
How is clopidogrel bisulphate regulated?
Clopidogrel bisulphate is regulated by health authorities worldwide, such as the FDA in the United States and the European Medicines Agency (EMA) in Europe. These agencies review and approve medications based on their safety, efficacy, and manufacturing quality [4].
---
Sources:
[1] https://www.drugpatentwatch.com/drug/clopidogrel
[2] https://www.drugpatentwatch.com/drug-patent-explorer/clopidogrel
[3] https://www.drugpatentwatch.com/drug-products/clopidogrel-bisulphate
[4] https://www.fda.gov/about-fda/center-drug-evaluation-and-research-celer/generics-medicine
[5] https://www.nhs.uk/medicines/clopidogrel/
[6] https://www.mayoclinic.org/drugs-supplements/clopidogrel-oral-route/side-effects/dr-20066369